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Abstract 
The aims of this study were to calculate bone lesion absorbed doses resulting from a weight-
based administration of 223Ra-dichloride, to assess the relationship between those doses 
and corresponding 18F-fluoride uptake and to assess the potential of quantitative 18F-fluoride 
imaging to predict response to treatment.  
 
Methods Five patients received two intravenous injections of 223Ra-dichloride, 6 weeks 
apart, at 110 kBq/kg whole-body weight. The biodistribution of 223Ra in metastatic lesions as 
a function of time after administration as well as associated lesion dosimetry were 
determined from serial 223Ra scans. PET/CT imaging using 18F-fluoride was performed prior 
to the first treatment (baseline), and at week 6 immediately before the second treatment and 
at week 12 after baseline. 
 
Results Absorbed doses to metastatic bone lesions ranged from 0.6 Gy to 44.1 Gy. For 
individual patients there was an average factor of 5.3 difference (range 2.5-11.0) between 
the maximum and minimum lesion dose. A relationship between lesion absorbed doses and 
serial changes in 18F-fluoride uptake was demonstrated (r2 = 0.52). A log-linear relationship 
was demonstrated (r2 = 0.77) between baseline measurements of 18F-fluoride uptake prior to 
223Ra-dichloride therapy and changes in uptake 12 weeks after the first cycle of therapy. 
Correlations were also observed between both 223Ra and 18F-fluoride uptake in lesions (r = 
0.75) as well as between 223Ra absorbed dose and 18F-fluoride uptake (r = 0.96).  
 
Conclusions There is both inter-patient and intra-patient heterogeneity of absorbed dose 
estimates to metastatic lesions.  A relationship between 223Ra lesion absorbed dose and 
subsequent lesion response was observed. Analysis of this small group of patients suggests 
that baseline uptake of 18F-fluoride in bone metastases is significantly correlated with 
corresponding uptake of 223Ra, the associated 223Ra absorbed dose and subsequent lesion 
response to treatment. 
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Introduction 
Prostate cancer is the most commonly diagnosed non-cutaneous malignancy in men [1]. A 
significant number of patients will present with metastatic disease in the bones. Hormonal 
therapy is used as a first line treatment but in many cases the disease will eventually cease 
to respond to hormonal therapies.  
 
In these circumstances, a range of palliative treatment options for bone metastases due to 
castration resistant prostate cancer (CRPC) are available, including a number of beta 
particle emitting radionuclides that are selectively taken up in areas of increased osteoblastic 
activity. Examples of such molecular radiotherapy treatments include 89Sr-chloride, 153Sm-
EDTMP, 186Re-HEDP and 188Re-HEDP. Due to the range of the beta particles potential 
irradiation of normal bone marrow is anticipated and haematological toxicity is the main side-
effect of such treatments [2]. 
 
Recently, treatment with 223Ra-dichloride has become available [3]. 223Ra is an alpha 
emitting radionuclide with a half-life of 11.4 days which also demonstrates increased uptake 
in regions of high osteoblastic activity. The short range of the alpha particles emitted (< 80 
m) enables high absorbed doses to be delivered to skeletal metastases whilst limiting the 
absorption of radiation within the bone marrow [4, 5]. 
 
The emissions from 223Ra include photons at energies that allow gamma camera imaging [6, 
7]. However patients receiving 23Ra-dichloride are typically injected with 55 kBq/kg body 
mass resulting in limited count statistics in the images.  As a result, tomographic imaging is 
impractical whilst 2D whole-body 223Ra images are characterised by significant levels of 
Poisson noise which can limit the positive identification of lesions for analysis. Nonetheless, 
two recent studies have used 2D gamma camera imaging to determine 223Ra absorbed 
doses according to the MIRD formalism, to measure  biodistribution and to calculate normal 
organ dosimetry in patients treated with 223Ra-dichloride [8, 9]. In addition, Carrasquillo et al 
[10] used 2D gamma camera imaging to demonstrate early bone uptake of 223Ra as well as 
small bowel excretion. 2D gamma camera images were also used by Pacilio et al [11] to 
calculate the absorbed dose to bone metastases in patients receiving 223Ra-dichloride 
therapy. Notably, this group reported a range of lesion absorbed doses with an order of 
magnitude difference between the lowest and highest values. Earlier studies of 223Ra 
therapy have already demonstrated a relationship between the activity administered to a 
particular cohort of patients (e.g. 25 kBq/kg vs 50 kBq/kg) and the average change in pain 
index or PSA level across those cohorts [12, 13].  However to date there has been no 
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evidence of a relationship between the lesion absorbed dose and response to treatment with 
223Ra-dichloride.  
 
18F-fluoride localises to the inorganic part of the bone, particularly in areas of osteoblastic 
activity, and has been used extensively for PET imaging of metastatic bone disease. Several 
studies have demonstrated superior sensitivity and specificity of 18F-fluoride imaging in 
comparison to conventional bone scintigraphy [14, 15].  Fluoride ions are incorporated into 
the hydroxyapatite crystal structure of the bone by substitution for hydroxyl (OH) ions. The 
relationship between osteoblastic and osteoclastic activity is believed to determine the 
amount of incorporation into the bone [16], given by. 
 
Ca10(PO4)6(OH)2 + F2
- Ca10(PO4)6(F)2 + 2OH
-     (1) 
 
In common with 18F-fluoride, 223Ra localises to areas of osteoblastic activity and the 
hydroxyapatite crystal structure is also thought to be the target for 223Ra ions [4]. These ions 
are taken up into bone by ionic exchange with the calcium ions [17]. Given the common 
hydroxyapatite target, it can be hypothesised that pre-treatment 18F-fluoride PET imaging 
may provide theragnostic information regarding the response of lesions to treatment with 
223Ra dichloride. 
 
In this study the cumulated activity, the effective half-life and the range of absorbed doses 
delivered to a number of lesions were determined. The relationship between 223Ra absorbed 
doses and subsequent changes in 18F-fluoride uptake in these lesions was also investigated. 
To our knowledge such dose-response data for 223Ra-dichloride therapy has not previously 
been published. Furthermore, the potential for a single pre-treatment assessment of 18F-
fluoride uptake to predict lesion response to 223Ra-dichloride treatment and to provide the 
basis for a surrogate dose-response relationship was investigated.             
 
 
Materials and Methods 
Data are presented from a post-hoc analysis of a phase I open-label clinical trial 
(NCT00667537) of 223Ra-dichloride in patients with bone metastases due to CRPC. Six 
patients with bone metastases from castration-resistant prostate cancer, as determined by 
99mTc-MDP bone scintigraphy no less than 6 weeks prior to treatment, were included in this 
study. Of the six patients recruited, five also underwent 18F-fluoride PET/CT imaging. Only 
these five patients were included in this post-hoc analysis. 
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Patients were scheduled to receive 100 kBq/kg of 223Ra-dichloride intravenously at baseline 
(therapy 1) and after 6 weeks (therapy 2). Following a revision of the primary standard for 
radionuclide calibrators [18, 19] it was retrospectively acknowledged that in fact patients 
received 110 kBq/kg. 18F-fluoride PET/CT imaging was performed at baseline up to 3 weeks 
before the first administration of 223Ra-dichloride, at 6 weeks just prior to the second 
administration of 223Ra-dichloride and at 12 weeks to assess treatment response. The mean 
age of patients that received both 223Ra-dichloride and 18F-fluoride was 63.2 years (range, 57 
to 70 years). Normal 223Ra organ dosimetry in these patients has previously been reported 
[8]. A description of the changes in 18F-fluoride uptake, concluding that 18F-fluoride could be 
used as a biomarker to monitor response to 223Ra-dichloride has also been previously 
reported [20] as were eligibility criteria [8, 20]. Approval for the study was obtained from the 
appropriate research ethics committees and the national Administration of Radioactive 
Substances Advisory Committee, and all patients provided written informed consent. 
 
 
99mTc-MDP Imaging 
Whole-body 99mTc-MDP images were acquired 3 hours after injection of 600 MBq 99mTc-
MDP. Imaging was performed on a Forte gamma camera (Philips Medical Systems, 
Cleveland, OH, US) using a low energy high resolution collimator according to a protocol 
previously detailed. Whole-body views were acquired for approximately 20 minutes using a 
matrix size of 256 x 1024. Imaging was performed using an energy window set at 140 +/- 
10% keV.  
 
 
223Ra Imaging 
Sets of whole-body 223Ra images were acquired in conjunction with each 223Ra-dichloride 
administration. Imaging was performed on a Forte gamma camera (Philips Medical Systems, 
Cleveland, OH, US) using a medium energy general purpose collimator according to a 
protocol previously detailed [6]. Whole-body and spot views were acquired for approximately 
30 minutes each using matrix sizes of 256 x 1024 and 256 x 256 pixels respectively. Imaging 
was performed using an energy window set at 82 +/- 20% keV. The first scan was acquired 
within 0 – 4 h post-injection and subsequent scans were acquired at 24, 48, 96 and 144 h 
post-injection. All images were acquired post-void to reduce artefacts due to radioactivity in 
the bladder. The count rate for all measurements was sufficiently low (< 1 kcts/s over the 
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entire spectrum counted by the camera) that no correction was required for detector dead-
time.  
 
223Ra Image Analysis & Dosimetry 
Regions of interest (ROIs) around 29 metastatic bone lesions were initially delineated on the 
anterior and posterior 99mTc-MDP whole-body images. Lesions corresponding to visible sites 
of increased 223Ra uptake were selected. For superscan patients (2/5), selected whole 
vertebrae were delineated as were the femoral heads. In one case an increased area of 
uptake in the right tibia was also selected. The 99mTc images were manually registered to the 
223Ra images using Hermes Hybrid Viewer (Hermes Medical, Sweden) to rigidly transform 
the images, thereby allowing transfer of the ROIs to the 223Ra whole-body and static images. 
The ROIs were then expanded in order to reduce the effect of spill-out due to partial volume 
effects and to limit the impact of any misregistration. Similarly to the work of Pacilio et al [11], 
a background correction for lesion uptake was determined from a region placed adjacent to 
the lesion ROI using the technique described by Buijs et al [21] whereby the background 
region was used to calculate an average background count per pixel. ROI delineation was 
performed by four observers comprising 3 experienced dosimetry physicists and 1 dual 
accredited consultant radiologist / nuclear medicine physician. The same consultant 
radiologist confirmed that all selected lesions were metastatic in nature. 
Activity quantification was performed on the patient images according to either the conjugate 
view method or the single view effective point source method [22]. The conjugate view 
method was applied to those lesions situated close to a point equidistant between the 
anterior and posterior patient surface at the level of the lesion. The single view method was 
used to quantify uptake in lesions close to either the anterior or posterior surface which were 
not visible on the opposite view. Image counts were converted to activity using measured 
sensitivity and attenuation correction factors for 223Ra as previously detailed [6]. The depth of 
a lesion within a patient was measured on the CT scan associated with the baseline 18F-
fluoride PET scan. 
Metastatic bone lesion volumes were measured by applying a Fuzzy Locally Adaptive 
Bayesian (FLAB) segmentation algorithm, initially developed for accurate outlining of PET 
data for radiotherapy planning, to the corresponding lesion sites on the baseline 18F-fluoride 
PET images. [23]. 
 
The decay constant  associated with the effective half-life, t1/2 eff and initial activity, A0, of 
223Ra in identified lesions was calculated by fitting a single exponential to the time activity 
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curve. The fit was constrained such that the effective half-life could not be greater than the 
physical half-life. Cumulated activity was calculated according to, 
 
?̃? =
𝐴0
𝜆
         (2) 
 
The total mean absorbed dose, D, to the target region included contributions from the decay 
of the daughter products of 223Ra (219Rn, 215Po, 211Pb, 211Bi, 211Po, 207Tl) The absorbed doses 
delivered to metastatic lesions by each isotope were calculated using self-irradiation S-
factors for unit density spheres [24],  scaled for an assumed bone density of 1.3 g ml-1 [25]. 
The absorbed dose is then given by 
 
𝐷 = ∑ [?̃? × 𝑆𝑖 × (
𝑉𝑆
𝑉𝑡 × 1.3
⁄ )]𝑖         (3) 
 
where Si is the self-irradiation S-Factor for isotope i and spherical volume Vs; and Vt is the 
lesion volume as determined by PET imaging. No radiation weighting factor was used to 
adjust the reported absorbed doses. It was assumed that the biodistribution of the daughter 
isotopes was the same as the 223Ra parent isotope [26]. 
 
18F-fluoride Imaging 
Repeated 18F-fluoride PET imaging was performed to assess treatment response. At each 
imaging time point, total body (vertex to feet) PET imaging was performed 1 h following 
injection of 250 MBq 18F-fluoride on a Gemini PET/CT scanner (Philips Medical Systems, 
Cleveland, OH, US). Data were acquired for 3.5 min per bed position following a low-current 
(50 mAs) CT scan performed for attenuation correction and lesion localisation.  
 
18F-fluoride Image Analysis 
18F-fluoride PET scans were assessed semi-quantitatively for evidence of response at the 6 
and 12-week time points compared to the baseline pre-treatment scan. In the case of one 
patient, the third PET scan was rejected for analysis due to technical problems with the 
image acquisition. FLAB derived outlines of the 29 lesions identified on 99mTc-MDP imaging 
were produced using an IDL routine incorporated into a Symbia.Net workflow (Siemens 
Healthcare, Germany). These were used to measure the SUVmean as well as the volume of 
each lesion. SUVmean values were corrected for partial volume effects as a function of lesion 
volume (Vt) using the following expression for recovery coefficient (RC) as described by 
Kessler et al [27] where  is the standard deviation of a Gaussian function describing the 
point spread function, determined by fitting equation 4 to the measured recovery curve 
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associated with an IEC NEMA image quality phantom filled with 18F. For the PET imaging 
described in this study a value of  = 4.3 mm was used. 
𝑅𝐶 = 𝑒𝑟𝑓 (
[3𝑉 4𝜋⁄ ]
1
3⁄
√2𝜎
) − √2 𝜋⁄ (
[3𝑉 4𝜋⁄ ]
1
3⁄
𝜎
) 𝑒
−(
[3𝑉 4𝜋⁄ ]
2
3⁄
2𝜎2
)
 (4) 
 
The patient body mass and lesion volumes were used to convert values of SUVmean to 
percentage injected activity (%IA). 
%𝐼𝐴 =
𝑆𝑈𝑉×𝑙𝑒𝑠𝑖𝑜𝑛 𝑣𝑜𝑙𝑢𝑚𝑒[𝑚𝑙]
(𝑝𝑎𝑡𝑖𝑒𝑛𝑡 𝑏𝑜𝑑𝑦 𝑚𝑎𝑠𝑠[𝑘𝑔]×1000)
   (5) 
Percentage changes in SUVmean relative to the baseline PET study were used to define the 
response to 223Ra-dichloride therapy on a lesion by lesion basis. Changes were measured at 
both 6 weeks and 12 weeks after baseline. Response to treatment after 6 weeks was plotted 
as a function of the 223Ra absorbed dose due to the first therapy. Response to treatment 
after 12 weeks was plotted as a function of the total 223Ra absorbed dose. 
 
 
18F-fluoride and 223Ra Comparison 
To test the hypothesis that 18F-fluoride uptake is predictive of both, 223Ra uptake and 
subsequent lesion response, the %IA of 18F in each lesion at baseline was compared to %IA 
of 223Ra at the time of the first therapy administration. Additionally, the %IA of 18F in each 
lesion at 6 weeks post therapy 1 was compared to %IA of 223Ra at the time of the second 
therapy administration. 
The SUVmean at baseline was compared to the calculated absorbed dose due to 
223Ra uptake 
in lesions. In addition, response to treatment at 6 weeks and 12 weeks post 223Ra-dichloride 
was plotted as a function of baseline SUVmean.. Figure 1 shows an example of all imaging 
(223Ra WB imaging, 99mTc WB imaging and 18F-fluoride PET/CT.) 
 
Uncertainty Analysis 
Data were analysed using Graphpad Prism software. The 223Ra lesion time activity curves 
were fitted with a mono-exponential function to estimate values for A0 and  as well as u(A0) 
and u(), the uncertainty in those estimates, and r(A0,) the covariance of A0 and . 
 
The overall uncertainty in the cumulated activity was calculated according to equation 6 [28]. 
The fractional uncertainty in the cumulated activity was used as an estimate of the fractional 
uncertainty in the absorbed dose estimate. 
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𝑢(?̃?) = ((
𝛿?̃?
𝛿𝐴0
)
2
𝑢2(𝐴0) + (
𝛿?̃?
𝛿𝜆
)
2
𝑢2(𝜆) + 2 (
𝛿?̃?
𝛿𝐴0
) (
𝛿?̃?
𝛿𝜆
) 𝑢(𝐴0, 𝜆))
0.5
= ((
1
𝜆
)
2
𝑢2(𝐴0) +
(
−𝐴0
𝜆2
)
2
𝑢2(𝜆) + 2 (
1
𝜆
) (
−𝐴0
𝜆2
) 𝑟(𝐴0, 𝜆)𝑢(𝐴0)𝑢(𝜆))
0.5
(6) 
  
The uncertainties associated with the 18F-Fluoride uptake measurements were derived from 
the results of Lin et al [29] who reported a coefficient of variation of 6.6% for lesion SUVmean.  
 
Statistical Analysis 
The distribution of absorbed doses and the log-transform of this distribution were tested for 
normality using the D’Agostino-Pearson criteria. The Kruskal-Wallis test and its associated 
p-value were used to compare the dose distributions resulting from the measurements of 
different observers. 
Spearman rank correlation coefficients and their associated p-values were calculated 
between the %IA of 18F-fluoride and 223Ra in the lesions as well as between the lesion 
SUVmean and the 
223Ra absorbed dose. Non-linear regression was performed to fit a log-
linear function to the absorbed dose-response data as well as to the relationship between 
baseline 18F-fluoride SUVmean and subsequent percentage changes in SUVmean following 
therapy. The fits were weighted by the uncertainty associated with the response 
measurements. Coefficients of determination were calculated for these fits. 
 
Results 
 
223Ra Image Analysis & Dosimetry 
A total of 29 metastatic lesions were identified on co-registered 99mTc-MDP and 223Ra WB 
images. The dosimetry results for these lesions are summarised in Table 1. Absorbed doses 
ranged from 0.6±0.3 Gy to 44.1±16.4 Gy with a median absorbed dose of 4.1 Gy (see Figure 
2). There was no significant difference in the observed absorbed doses determined from the 
lesion outlines of each operator (p=0.58). The log-transform of each distribution was found to 
be normally distributed. The median uncertainty in the lesion dose calculations (±1.0 Gy) 
was more than an order of magnitude less than the range of the calculated values. 
Approximately 80% of the absorbed dose in each lesion was due to alpha and beta particles 
emitted from the daughter isotopes. A full breakdown of the relative contribution of each 
isotope is given in Table 2. The effective half-life of 223Ra in lesions ranged from 44 hours to 
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274 hours (the physical half-life) with a median effective half-life of 136 hours (See Figure 
3)). 
A significant high correlation was observed between lesion uptake (A0) at the time of the first 
therapy and the time of the second therapy 6 weeks later (r = 0.88, p < 0.0001). The 
relationship between the effective half-life of 223Ra measured at the two different time points 
was also significantly correlated (r = 0.77, p < 0.0001) as was the relationship between the 
lesion absorbed doses (r = 0.85, p < 0.0001). These relationships are shown in Figure 4. 
 
223Ra – 18F-fluoride dose response relationship 
The relationship between lesion absorbed dose and the observed response as defined by 
percentage change in the 18F-fluoride SUVmean relative to baseline are shown in Figure 5. 
After 6 weeks there is no evident relationship between lesion dose and response (r2 = 0.07). 
However after 12 weeks there is an apparent log-linear relationship (r2 = 0.54) between the 
total absorbed dose from both therapies and the changes in the 18F-fluoride uptake. Based 
on the analysis of test-retest 18F-fluoride PET/CT imaging, Kurdziel et al [30] suggested a 
minimum percentage change of 21% should be used to identify real change in the SUVmean 
between two sequential scans of 18F-fluoride acquired 60 minutes post injection. For a 
change of > 21% in SUVmean of a lesion, a threshold of 5.0 Gy correctly identifies 94% of all 
responding lesions whilst no non-responding lesions are incorrectly identified as responding. 
18F-fluoride and 223Ra Comparison 
The relationship between %IA 223Ra and %IA 18F-fluoride is shown in Figure 6. A significant 
high correlation (r=0.71, p<0.0001) was observed. Furthermore, a high correlation is 
demonstrated between therapy 1 lesion absorbed dose and baseline 18F-fluoride SUVmean (r 
= 0.77, p<0.0001) as well as between therapy 2 lesion absorbed dose and 18F-fluoride 
SUVmean at 6 weeks (p<0.0001). (Figure 7.) 
 
 
18F-fluoride Image Analysis 
Figure 8 shows a log-linear dose response relationship between baseline SUVmean prior to 
treatment and the lesion responses as defined by percentage changes in SUVmean. In 
common with the 223Ra dose-response relationship, no significant relationship was observed 
6 weeks after the first treatment. However at 12 weeks after the first treatment, a well-
defined log linear relationship was observed (r2 = 0.77).  If response is again defined as a 
change of >21% in the SUVmean of a lesion then a threshold between 17-20 partial volume 
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corrected SUVmean correctly identifies 100% of all responding lesions whilst no non-
responding lesions are incorrectly identified as responding.  
 
 
 
 
Discussion  
Absorbed doses in metastatic bone lesions ranged from 0.6 Gy to 44.1 Gy in this study. I.e. 
there is significant heterogeneity of absorbed dose across the patient population.  For 
individual patients there was an average factor of 5.3 difference (range 2.5-11.0) between 
the maximum and minimum lesion dose. Emissions from the daughter isotopes of 223Ra 
contributed between 79% – 84% of this absorbed dose. The absorbed doses from 223Ra 
emissions only were 0.1 – 9.4 Gy which encompass the range observed in the study by 
Pacilio et al [11]. For deterministic cell killing effects using alpha emitters, a factor of 5 for 
relative biological effectiveness (RBE) has been suggested [31, 32]. However, this has not 
been validated in human studies and therefore no corrections for RBE were made to the 
dosimetry data presented in this study.  
The limited count statistics associated with 223Ra whole-body imaging lead to uncertainties in 
the fitting of the time activity curves which in turn leads to the propagation of further 
uncertainty in the estimation of the absorbed dose. In this study the uncertainty associated 
with the absorbed dose estimates ranged from 0.03 Gy to 16.4 Gy. Nevertheless the median 
uncertainty in the lesion dose calculations (±1.0 Gy) was an order of magnitude less than the 
range of the calculated values and interobserver variation was not significant. No correlation 
was observed between uncertainty and lesion volume, nor between lesion absorbed dose 
and lesion volume.  One way of reducing the uncertainty associated with these absorbed 
dose estimates could be to change the time points at which 223Ra images are acquired. In 
our study, the latest imaging time points were at 6 days after administration. Pacilio et al [11] 
imaged patients up to 24 days after administration, approximately 4 times the median 
effective half-life observed in our cohort and more in alignment with the MIRD 
recommendations for appropriate temporal sampling [22]. 
A further source of uncertainty associated with molecular radiotherapy dosimetry is the 
estimation of lesion volume. In this study, the FLAB segmentation technique was used to 
measure volume. This technique developed for radiotherapy outlining has been shown to be 
both accurate and reproducible [33]. The use of this particular algorithm reduces inter-
operator variability in measurements of lesion volume to approximately 1% compared to 
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~15% for manual delineation [34]. In the example image shown in Figure 1, the PET derived 
outline of a rib lesion is seen to closely match the bony anatomy of the lesion demonstrated 
by the CT imaging. However, the use of a macroscopic volume is likely to give rise to a 
systematic error in the dose estimation since the true target volume, the endosteal layer, is 
an unknown fraction of the outlined volume. 
Despite these uncertainties, a relationship between the absorbed dose to a lesion delivered 
over two cycles of therapy and the subsequent response as measured by 18F-fluoride 
imaging was demonstrated. The lack of an early response to 223Ra treatment has previously 
been observed and it was suggested that the flare phenomenon, whereby an increase in 18F-
fluoride uptake is observed following treatment, may be partly responsible for this [35].  
The hypothesised relationship between 18F-fluoride and 223Ra uptake was demonstrated 
(see Figure 6). The relationship is similar to the linear relationship between 223Ra and 99mTc-
MDP uptake previously demonstrated by Pacilio et al [11]. A strong correlation between 18F-
fluoride uptake and 223Ra absorbed dose was also observed, despite a wide range in the 
223Ra lesion effective half-life. 
The association between the 18F-fluoride uptake and 223Ra absorbed dose may therefore 
explain the apparent dose-response relationship between the SUVmean of a lesion measured 
prior to treatment with 223Ra-dichloride and the subsequent changes in SUVmean following two 
administrations of 223Ra-dichloride (Figure 8).  
The potential for 18F-fluoride to act as a surrogate measure of 223Ra absorbed dose is 
appealing for a number of reasons. First, there is a higher coefficient of determination (r2 
value) between the 18F-fluoride SUVmean and the lesion response (r
2 = 0.77, Figure 8B) 
compared to that between the lesion absorbed dose and the lesion response (r2 = 0.52, 
Figure 5B). I.e. the 18F-fluoride uptake at baseline is a better indicator of the subsequent 
response than the absorbed dose estimate. This may reflect the greater uncertainty 
associated with the calculation of 223Ra absorbed dose from low count planar data. Second, 
the measurement of mean SUV within a lesion is an analysis technique more commonly 
used in routine clinical practice than the analysis of serial whole body images to calculate 
absorbed doses, although such dosimetry methodology is well established. Finally, the 
advantage of a surrogate measure for absorbed dose derived from a pre-treatment 18F-
fluoride PET scan is that it represents prospective theragnostic information that could enable 
personalised treatment planning.  
Earlier studies of 223Ra therapy have already demonstrated a relationship between the 
activity administered to a particular cohort of patients (e.g. 25 kBq/kg vs 50 kBq/kg) and the 
average change in pain index or PSA level across those cohorts [12, 13]. The wide range in 
the absorbed dose across multiple metastatic sites, along with the ability to image that dose 
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distribution, either directly or through surrogate 18F-fluoride PET imaging, suggests that there 
is scope to further optimise the delivery of 223Ra-dichloride treatment at an individual level. 
This study is limited by the number of patients recruited to the trial. In particular, the upper 
end of the dose-response curves could be better defined by additional data points. 
Nonetheless, if the relationship between initial 18F-fluoride and the subsequent response to 
therapy observed in this investigation can be replicated in a larger patient cohort, 18F-fluoride 
PET imaging can potentially provide a quantitative method for optimising the potential of 
223Ra-dichloride treatment for individual patients. 
Therefore future trials would need to address several issues.  Whilst this study suggests that 
the individual lesion absorbed doses are predictive of subsequent changes observed with 
functional imaging, the relationship between absorbed dose and other clinically relevant 
endpoints including pain index, changes in ALP or PSA levels or prolonged survival should 
be investigated and quantified. This would further support the previous analysis of these 
patients by Cook et al [20] that described a qualitative association between changes in the 
average SUVmax of selected lesions and changes in ALP and PSA.  
In this study a relationship between 18F-fluoride uptake, 223Ra absorbed dose and lesion 
response was demonstrated for two treatments of 110 kBq/kg. Further studies are required 
to investigate these results for alternative administration schedules including the current 
standard regimen of 6 x 55kBq/kg. The relationship between baseline uptake of 18F-fluoride 
and response to two treatments of 100 kBq/kg demonstrated that non-responding lesions 
could be identified prior to therapy. This leads to the hypothesis that a subset of patients who 
would benefit from increased activities of 223Ra-dichloride could be identified. Again, a 
suitably designed clinical trial would be required to test this hypothesis. 
 
 
 
 
Conclusion 
223Ra lesion dosimetry performed using planar WB and static images of 223Ra distribution 
show a wide range of absorbed doses across multiple sites of metastases. Evidence of a 
relationship between the 223Ra absorbed dose to a lesion and the subsequent response 
defined by serial 18F-Fluoride imaging was observed. 
A relationship was also observed between the 18F-Fluoride uptake prior to 223Ra-dichloride 
treatment and the subsequent lesion response, indicating that 18F-fluoride SUVmean could 
potentially act as a predictor of lesion absorbed dose. This is likely due to the fact that 
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uptake of 18F-fluoride in bone metastases is significantly correlated with both the 
corresponding uptake of 223Ra and the associated 223Ra absorbed dose. Larger trials are 
required to confirm these initial findings as well as to explore potential methodologies for 
optimising treatment. 
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Table 1: 223Ra Lesion Dosimetry 
Patient 
number 
Lesion Site Vol 
[ml] 
Therapy  Absorbed 
Dose [Gy] 
(
223
Ra and 
daughter 
isotopes) 
Effective 
Half-life 
[hrs] 
1 T5 vertebra 5.9 1 10.2 ± 1.5 273.6 ± 0.0* 
2 11.3 ± 2.3 237.5 ± 180.9 
Left femoral 
head 
29.1 1 3.6 ± 0.7 273.6 ± 0.0* 
2 4.7 ± 0.2 273.6 ± 0.0* 
C4 vertebra 8.5 1 10.9 ± 1.6 273.6 ± 0.0* 
2 11.2 ± 1.2 273.6 ± 0.0* 
Right SI joint 6.6 1 6.2 ± 1.1 273.6 ± 0.0* 
2 8.5 ± 0.4 181.7 ± 23.8 
S1 vertebra 7.7 1 3.8 ± 0.6 273.6 ± 0.0* 
2 4.3 ± 0.9 273.6 ± 0.0* 
L3 vertebral 
process 
3.7 1 7.3 ± 3.3 157.0 ± 141.0 
2 10.0 ± 1.7 273.6 ± 0.0* 
Left pelvis 
(ischeum) 
5.5 1 3.4 ± 1.0 273.6 ± 0.0* 
2 4.4 ± 1.4 273.6 ± 0.0* 
2 L5 vertebra 41.2 1 6.2 ± 0.3 159.9 ± 23.7 
2 4.2 ± 0.7 127.4 ± 47.3 
T12 vertebra 1.2 1 43.8 ± 11.2 143.0 ± 100.1 
2 44.1 ± 16.4 66.6 ± 50.6 
R pelvis 7.1 1 4.9 ± 0.8 83.8 ± 24.9 
2 17.5 ± 2.9 218.9 ± 198.1 
L3 vertebra 5.6 1 10.4 ± 0.9 108.5 ± 22.1 
2 5.5 ± 0.5 102.6 ± 19.2 
R Rib9 2.8 1 6.4 ± 1.2 92.7 ± 36.7 
2 4.0 ± 0.9 59.5 ± 24.5 
Sternum 18.7 1 6.0 ± 0.4 91.0 ± 12.2 
2 5.2 ± 0.2 91.4 ± 7.7 
3 Right Skull  39.9 
 
1 1.6 ± 0.3 135.7 ± 90.1 
2 1.1 ± 0.2 94.6 ± 30.6 
Left Skull 1.9 
 
1 1.5 ± 1.0 84.4 ± 153.3 
2 1.5 ± 0.7 136.9 ± 162.4 
T11 vertebra 9.2 
 
1 4.9 ± 0.6 76.3 ± 23.2 
2 5.8 ± 1.2 83.8 ± 35.0 
L3 vertebra 10.8 
 
1 1.5 ± 0.7 141.2 ± 282.8 
2 5.3 ± 1.8 76.5 ± 47.8 
L4 vertebra 22.9 
 
1 1.7 ± 0.8 61.1 ± 69.7 
2 2.6 ± 0.3 71.7 ± 17.1 
Right Rib 7 13.9 1 4.0 ± 1.3 92.0 ± 41.0 
2 2.7 ± 0.5 61.0 ± 20.2 
4 L2 vertebra 39.4 1 0.6 ± 0.3 70.9 ± 51.7 
2 1.0 ± 0.2 44.4 ± 20.3 
L3 vertebra 56.4 1 1.0 ± 0.4 66.8 ± 37.8 
2 1.0 ± 0.2 45.0 ± 17.1 
T12 vertebra 32.0 1 1.5 ± 0.1 178.3 ± 27.7 
2 1.2 ± 0.2 94.1 ± 7.7 
L femoral head 68.9 1 1.4 ± 0.1 114.4 ± 25.6 
2 1.1 ± 0.1 78.3 ± 12.0 
R femoral head 67.5 1 1.1 ± 0.2 94.0 ± 31.9 
2 1.0 ± 0.2 98.3 ± 34.9 
5 L1 vertebra 45.5 1 1.8 ± 0.3 112.0 ± 43.6 
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 2 2.5 ± 0.2 240.7 ± 81.9 
T11 vertebra 
 
42.3 1 2.2 ± 0.3 145.5 ± 53.2 
2 3.0 ± 0.0 232.0 ± 8.8 
Right Femoral 
Head 
59.0 1 8.1 ± 0.5 273.6 ± 0.0* 
2 7.0 ± 0.5 273.6 ± 0.0* 
Left Femoral 
Head 
105.0 1 3.6 ± 0.3 261.5 ± 87.3 
2 3.4 ± 0.0 257.2 ± 11.8 
Right tibia 66.8 1 
2 
5.7 ± 0.9 168.2 ± 86.7 
8.3 ± 1.3 273.6 ± 0.0* 
 
Table 1: List of lesions, their location and estimated absorbed doses. * no uncertainty estimate of 
effective half-life was possible where the monoexponential fit reached  the constraint of 
223
Ra physical 
half-life .  
 
 
Table 2: Relative absorbed dose from Ra223 and daughter isotopes 
Isotope Contribution to total lesion 
dose [%] 
Ra-223 21.3 
Rn-219 24.6 
Ra-215 26.9 
Pb-211 1.6 
Bi-211 23.9 
Po-211 0.1 
Tl-207 1.7 
Table 2: Relative contribution of each isotope to lesion absorbed dose.
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Figure 1: Examples of acquired images for patient 2. A) and C) show 
99m
Tc-MDP whole-body imaging. B) and D) show 
223
Ra WB imaging 6 days after therapy 
administration. Arrows indicate uptake in posterior right rib. E) 
18
F-Fluoride PET/CT imaging at baseline including FLAB outlining of posterior right rib lesion used 
for volume estimation. 
A B C D E 
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Figure 2: Histogram of lesion absorbed dose. Data are shown for 29 lesions measured from 5 patients. 
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Figure 3: Histogram of lesion effective half-life. Data are shown for 29 lesions measured from 5 patients. 
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Figure 4: Relationship between estimated absorbed dose parameters for therapy 1 and therapy 2.  A) 
Initial lesion uptake of 
223
Ra, B) of 
223
Ra lesion effective half-life and C) lesion absorbed dose. 
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Figure 5: Lesion response to 
223
Ra-dichloride treatment. (n=24 over 4 patients) A) Response to therapy 1 
only assessed 6 weeks after baseline. B) Response to therapy 1 and 2 assessed 12 weeks after baseline. 
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Figure 6: Relationship between 
223
Ra uptake and 
18
F-Fluoride uptake. n = 58. 
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Figure 7: Relationship between 
223
Ra absorbed dose to lesion and lesion 
18
F-fluoride SUVmean at the time 
of treatment. A) Dose from Therapy 1 vs Baseline PET. B) Absorbed dose from Therapy 2 vs 6 week PET. 
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Figure 8: Relationship between baseline SUVmean and subsequent response to 
223
Ra dichloride. A) 
Changes following one cycle of 
223
Ra-dichloride. B) Changes following two cycles of 
223
Ra-dichloride. 
(n=24 over 4 patients)   
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